Skip to content

Usage of Biological Patch Versus Plastic in the Laparoscopic Repair of Hiatal Hernias

Randomized Control Trial (RCT) That the Usage With Biological Patch Versus Plastic in the Laparoscopic Repair

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02328248
Enrollment
150
Registered
2014-12-31
Start date
2014-07-31
Completion date
2016-12-31
Last updated
2014-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hiatal Hernia

Brief summary

The purpose of this study is to observe the effective and safety in the laparoscopic repair of hiatal hernia using biological patch versus plastic.

Detailed description

observation indicator: 1. incidence rate of complications, 2. postoperative hospital stay 3. readmission rate in 1st month after operation 4. recurrence rate after operation 5. hospitalization costs 6. Self-evaluation of gastroesophageal reflux symptoms and quality of life(QOL) in 6th-month, 1st-year,2nd-year,3rd-year,4th-year and 5th-year after operation

Interventions

PROCEDUREBiological patch

Use biological patch as opposed to plastic patch to repair hiatal hernia laparoscopically

Sponsors

Xijing Hospital of Digestive Diseases
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of Hiatal hernia * Consistent with operation indications throughout the guideline of hiatal hernia by the Chinese Medical Association in 2003 * randomly select patch agreed by patients and family members

Exclusion criteria

* Poor general condition * severe organ dysfunction * No-tolerate anesthesia * No-suitable for operation * Emergency operation needed * Serious adverse events appeared during the operation * Sever intraperitoneal adhesion existed * glucocorticoid with long-term use * immunocompromised patients * spirit disease patients * automatically exit * women who pregnant

Design outcomes

Primary

MeasureTime frame
The incidence of complications in all casefive years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026